| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | EX-527 | CTRPv2 | pan-cancer | AAC | 0.0095 | 0.8 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.019 | 0.8 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | Topotecan | FIMM | pan-cancer | AAC | 0.028 | 0.8 |
| mRNA | ATRA | GDSC1000 | pan-cancer | AAC | 0.008 | 0.8 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | -0.0082 | 0.8 |
| mRNA | LFM-A13 | GDSC1000 | pan-cancer | AAC | 0.008 | 0.8 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0071 | 0.8 |
| mRNA | EHT 1864 | GDSC1000 | pan-cancer | AAC | -0.0077 | 0.8 |
| mRNA | BRD-K90370028 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |